Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Outlook Therapeutics Announces New Employment Inducement Grants GlobeNewswire - Fri Dec 26, 4:00PM CST

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 1.8650 (-5.81%)
OTLKW : 0.03 (-1.96%)
GDP in Canadian Spotlight Next Week Baystreet - Sun Dec 21, 10:27PM CST

Monday U.S. Featured Earnings Bridgeline Digital Inc (NASDAQ: BLIN) (Q4) EPS ...

BLIN : 0.8996 (+13.30%)
OTLK : 1.8650 (-5.81%)
LMNR : 12.47 (+0.40%)
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 GlobeNewswire - Fri Dec 19, 7:05AM CST

ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 1.8650 (-5.81%)
OTLKW : 0.03 (-1.96%)
Micron Technology Inc_billboard-by Poetra_RH via Shutterstock
Micron Dominates Barchart's Top 100 with Killer Volume—Your Buy Signal? Barchart - Tue Dec 16, 10:39AM CST

In Monday’s trading, Micron Technology jumped 14 spots in Barchart’s Top 100 Stocks to Buy, into 36th position. Of the top 100, Micron’s price volume was the highest at 6.53 million, nearly four...

IREN : 38.30 (-2.82%)
OTLK : 1.8650 (-5.81%)
NVDA : 187.54 (-0.36%)
MU : 292.63 (-0.59%)
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Mon Nov 24, 8:05AM CST

ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 1.8650 (-5.81%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD GlobeNewswire - Thu Nov 13, 7:30AM CST

Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused...

OTLK : 1.8650 (-5.81%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 GlobeNewswire - Mon Nov 3, 7:35AM CST

ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of...

OTLK : 1.8650 (-5.81%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Update on Type A Meeting with FDA GlobeNewswire - Mon Sep 29, 7:45AM CDT

ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.   (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment...

OTLK : 1.8650 (-5.81%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Requests Type A Meeting with FDA GlobeNewswire - Tue Sep 2, 7:35AM CDT

ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment...

OTLK : 1.8650 (-5.81%)
OTLKW : 0.03 (-1.96%)
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug Zacks Investment Research - Fri Aug 29, 10:42AM CDT

Shares of Outlook Therapeutics OTLK tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related...

OTLK : 1.8650 (-5.81%)
KNSA : 40.99 (-0.01%)
CRMD : 12.48 (-1.96%)
PHAR : 16.81 (-0.71%)

Barchart Exclusives

Is Ford a Dividend Stock Worth Buying for 2026 After Its 34% Rise This Year? Barchart - Tue Dec 30, 6:30PM CST
While Ford is up 34% for the year and has a healthy dividend yield of 4.5%, the stock's 2026 forecast does not look too bright. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot